This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
Merit Medical (MMSI) Expands Drainage Portfolio With New Product
by Zacks Equity Research
Merit Medical's (MMSI) new commercial product launch can make sample collection simple, safe and efficient.
HealthEquity (HQY) Loses 8.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
HealthEquity (HQY) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
HealthEquity (HQY) has been struggling lately, but the selling pressure may be coming to an end soon.
MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on
by Debanjana Dey
Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.
Why Is HealthEquity (HQY) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Add HealthEquity Stock (HQY) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity (HQY) on its slew of buyouts and strength in HSA.
Top Ranked Momentum Stocks to Buy for June 14th
by Zacks Equity Research
ESEA, OXM, TRNS, and HQY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 14, 2021.
HealthEquity (HQY) Q1 Earnings Beat Estimates, FY22 View Up
by Zacks Equity Research
HealthEquity (HQY) delivers solid growth in HSAs along with recording robust Interchange revenues in the first quarter of fiscal 2022.
Earnings Preview: HealthEquity (HQY) Q1 Earnings Expected to Decline
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: HealthEquity, NeoGenomics, Howard Hughes Corp and StoneCo
by Zacks Equity Research
Zacks.com featured highlights include: HealthEquity, NeoGenomics, Howard Hughes Corp and StoneCo
Don't Let These 4 Toxic Stocks Erode Your Wealth
by Rimmi Singhi
Spotting bloated toxic stocks on a regular basis and abandoning them at the right time is one of the secrets to a winning investment strategy.
PINC or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands
by Zacks Equity Research
Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands
5 Toxic Stocks That Could Break the Bank
by Rimmi Singhi
Steer clear of toxic stocks like MELI, HQY, DXCM, STNE and LVS to safeguard your portfolio.
HealthEquity (HQY) Down 13.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 19th
by Zacks Equity Research
APT, HQY and MFIN have been added to the Zacks Rank #5 (Strong Sell) List on March 19, 2021
HealthEquity (HQY) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivers solid growth in HSAs and custodial assets in the fiscal fourth quarter.
HealthEquity (HQY) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 2.44% and 1.40%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for HealthEquity (HQY) This Earnings Season?
by Radhika Saraogi
HealthEquity (HQY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HealthEquity (HQY) Enhances Commuter Offering With New Buyout
by Zacks Equity Research
HealthEquity's (HQY) buyout of Luum will strengthen the former's potential for new hybrid workplace as well as provide safe and affordable commuting options to employees.
HealthEquity (HQY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why HealthEquity (HQY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why the Earnings Surprise Streak Could Continue for HealthEquity (HQY)
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.